CSEM and ClexBio create a bioreactor for tissue-engineered cardiovascular implants
A new type of bioreactor that can grow human veins in the lab has been developed by CSEM and ClexBio, a Nordics-based startup specialized in regenerative medicine. Funded by the Research Council of Norway, their solution aims to improve the lives of millions of people suffering from severe chronic venous insufficiency (CVI) by providing them with bio-engineered vein implants.
Related Press
24 June 2021
CUTISS
CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has unveiled the world’s first automated machine to produce customized skin tissue...
3 February 2023
Making personalized cancer therapies accessible to all
CSEM has supported Lausanne-based start-up Limula in its mission to make cell therapies more affordable, and to facilitate access to these personalized treatments. ...
28 June 2022
Supervene: the new treatment for venous insufficiency
ClexBio and CSEM team up to develop the first machine for manufacturing vein implants. ...